Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience

Brain Research

Volumn 1293, Issue , 2009, Pages 13-23

  Krystal, John H ^a   Neumeister, Alexander ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Center for PTSD   (United States)

Author keywords

Neuropeptides; Norepinephrine; PTSD; Resilience; Serotonin; Stress

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; DOPAMINE; NEUROPEPTIDE Y; NEUROSTEROID; NORADRENALIN; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AVOIDANCE BEHAVIOR; COPING BEHAVIOR; DEPRESSION; DRUG ACTIVITY; HUMAN; NEUROBIOLOGY; NORADRENERGIC SYSTEM; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

ADAPTATION, PSYCHOLOGICAL; HUMANS; NEURONS; NOREPINEPHRINE; SEROTONIN; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL; SYMPATHETIC NERVOUS SYSTEM; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 70149104805     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.03.044     Document Type: Review

References (105)

1. Alim T.N., Feder A., Graves R.E., Wang Y., Weaver J., Westphal M., Alonso A., Aigbogun N.U., Smith B.W., Doucette J.T., Mellman T.A., Lawson W.B., and Charney D.S. Trauma, resilience, and recovery in a high-risk African-American population. Am. J. Psychiatry 165 (2008) 1566-1575
2. Amato J.L., Bankson M.G., and Yamamoto B.K. Prior exposure to chronic stress and MDMA potentiates mesoaccumbens dopamine release mediated by the 5-HT(1B) receptor. Neuropsychopharmacology 32 4 (2007) 946-954
3. Arnsten A.F. The biology of being frazzled. Science 280 (1998) 1711-1712
4. Arnsten A.F., and Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 57 (2005) 1377-1384
5. Arnsten A.F., Steere J.C., Jentsch D.J., and Li B.M. Noradrenergic influences on prefrontal cortical cognitive function: opposing actions at postjunctional alpha 1 versus alpha 2-adrenergic receptors. Adv. Pharmacol. 42 (1998) 764-767
6. Arnsten A.F., Mathew R., Ubriani R., Taylor J.R., and Li B.M. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol. Psychiatry 45 (1999) 26-31
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Vol. (1994), American Psychiatric Association, Washington, DC
8. Avery R.A., Franowicz J.S., Studholme C., van Dyck C.H., and Arnsten A.F. The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 23 (2000) 240-249
9. Bonanno G.A., Galea S., Bucciarelli A., and Vlahov D. What predicts psychological resilience after disaster? The role of demographics, resources, and life stress. J. Consult. Clin. Psychol. 75 (2007) 671-682
10. Bonne O., Bain E., Neumeister A., Nugent A.C., Vythilingam M., Carson R.E., Luckenbaugh D.A., Eckelman W., Herscovitch P., Drevets W.C., and Charney D.S. No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. Am. J. Psychiatry 162 (2005) 383-385
11. Boscarino J.A. Posttraumatic stress disorder and mortality among U.S. Army veterans 30 years after military service. Ann. Epidemiol. 16 (2006) 248-256
12. Bremner J.D., Innis R.B., Ng C.K., Staib L.H., Salomon R.M., Bronen R.A., Duncan J., Southwick S.M., Krystal J.H., Rich D., Zubal G., Dey H., Soufer R., and Charney D.S. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch. Gen. Psychiatry 54 (1997) 246-254
13. Breslau N., Kessler R.C., Chilcoat H.D., Schultz L.R., Davis G.C., and Andreski P. Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Arch. Gen. Psychiatry 55 (1998) 626-632
14. Breslau N., Chilcoat H.D., Kessler R.C., Peterson E.L., and Lucia V.C. Vulnerability to assaultive violence: further specification of the sex difference in post-traumatic stress disorder. Psychol. Med. 29 (1999) 813-821
15. Breslau N., Peterson E.L., and Schultz L.R. A second look at prior trauma and the posttraumatic stress disorder effects of subsequent trauma: a prospective epidemiological study. Arch. Gen. Psychiatry 65 (2008) 431-437
16. Brewin C.R., Andrews B., and Valentine J.D. Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. J. Consult. Clin. Psychol. 68 (2000) 748-766
17. Bruening S., Oh E., Hetzenauer A., Escobar-Alvarez S., Westphalen R.I., Hemmings Jr. H.C., Singewald N., Shippenberg T., and Toth M. The anxiety-like phenotype of 5-HT receptor null mice is associated with genetic background-specific perturbations in the prefrontal cortex GABA-glutamate system. J. Neurochem. 99 (2006) 892-899
18. Carli M., Afkhami-Dastjerdian S., and Reader T.A. [3H]8-OH-DPAT binding and serotonin content in rat cerebral cortex after acute fluoxetine, desipramine, or pargyline. J. Psychiatry Neurosci. 21 (1996) 114-122
19. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res. Brain Res. Rev. 18 (1993) 1-32
20. Chaouloff F., Berton O., and Mormede P. Serotonin and stress. Neuropsychopharmacology 21 (1999) 28S-32S
21. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., and Heninger G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch. Gen. Psychiatry. 45 (1988) 177-185
22. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., Watanabe N., Nakagawa A., Omori I.M., McGuire H., Tansella M., and Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373 9665 (2009) 746-758
23. 1B receptor: behavioral implications. Psychopharmacol. Bull. 35 (2001) 170-185
24. Clark C.R., McFarlane A.C., Morris P., Weber D.L., Sonkkilla C., Shaw M., Marcina J., Tochon-Danguy H.J., and Egan G.F. Cerebral function in posttraumatic stress disorder during verbal working memory updating: a positron emission tomography study. Biol. Psychiatry 53 (2003) 474-481
25. 1B receptor in dorsal raphe nucleus using herpes simplex virus gene transfer increases anxiety behavior after inescapable stress. J. Neurosci. 22 (2002) 4550-4562
26. Davidson J.R. Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson trauma scale, clinical global impressions and the clinician-administered PTSD scale. Int. Clin. Psychopharmacol. 19 (2004) 85-87
27. Davis L.L., Ward C., Rasmusson A., Newell J.M., Frazier E., and Southwick S.M. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol. Bull. 41 (2008) 8-18
28. de Lange R.P., Wiegant V.M., and Stam R. Altered neuropeptide Y and neurokinin messenger RNA expression and receptor binding in stress-sensitised rats. Brain Res. 1212 (2008) 35-47
29. Dieperink M., Erbes C., Leskela J., Kaloupek D., Farrer M.K., Fisher L., and Wolf E. Comparison of treatment for post-traumatic stress disorder among three Department of Veterans Affairs medical centers. Mil. Med. 170 (2005) 305-308
30. Ding Y.S., Lin K.S., Logan J., Benveniste H., and Carter P. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J. Neurochem. 94 (2005) 337-351
31. DuMont K.A., Widom C.S., and Czaja S.J. Predictors of resilience in abused and neglected children grown-up: the role of individual and neighborhood characteristics. Child Abuse Negl. 31 (2007) 255-274
32. Dunn A.J. Changes in plasma and brain tryptophan and brain serotonin and 5-hydroxyindoleacetic acid after footshock stress. Life Sci. 42 (1988) 1847-1853
33. Eaton K., Sallee F.R., and Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top Med. Chem. 7 (2007) 1645-1659
34. Franowicz J.S., Kessler L.E., Borja C.M., Kobilka B.K., Limbird L.E., and Arnsten A.F. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 22 (2002) 8771-8777
35. 1A-mediated responses: effect on treatments that modify serotonergic neurotransmission. In: Whitaker-Azmitia P.M., and Peroutka S.J. (Eds). The Neuropharmacology of Serotonin. Vol. (1990), The New York Academy of Sciences, New York 460-475
36. Galletly C., Clark C.R., McFarlane A.C., and Weber D.L. Working memory in posttraumatic stress disorder-an event-related potential study. J. Trauma. Stress 14 (2001) 295-309
37. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., and Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84 (1998) 413-429
38. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65 (1995) 319-395
39. 1A receptor knockout mice and mice overexpressing corticotropin-releasing hormone in models of anxiety. Eur. J. Pharmacol. 463 (2003) 185-197
40. 1B receptor knockout mice in stress and anxiety paradigms. Behav. Pharmacol. 14 (2003) 369-383
41. Gutman A.R., Yang Y., Ressler K.J., and Davis M. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J. Neurosci. 28 (2008) 12682-12690
42. Habecker B.A., Willison B.D., Shi X., and Woodward W.R. Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J. Neurochem. 97 (2006) 1044-1051
43. Harvey B.H., Naciti C., Brand L., and Stein D.J. Serotonin and stress: protective or malevolent actions in the biobehavioral response to repeated trauma?. Ann. N. Y. Acad. Sci. 1032 (2004) 267-272
44. 1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26 (2002) 565-573
45. Hoebel B.G., Avena N.M., and Rada P. Accumbens dopamine-acetylcholine balance in approach and avoidance. Curr. Opin. Pharmacol. 7 (2007) 617-627
46. Hoge C.W., Terhakopian A., Castro C.A., Messer S.C., and Engel C.C. Association of posttraumatic stress disorder with somatic symptoms, health care visits, and absenteeism among Iraq war veterans. Am. J. Psychiatry 164 (2007) 150-153
47. 1B receptor and 5-HT2B receptors. Mol. Pharmacol. 71 (2007) 1463-1474
48. Kessler R.C., Sonnega A., Bromet E., Hughes M., and Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 52 (1995) 1048-1060
49. Kilpatrick D.G., Koenen K.C., Ruggiero K.J., Acierno R., Galea S., Resnick H.S., Roitzsch J., Boyle J., and Gelernter J. The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. Am. J. Psychiatry 164 (2007) 1693-1699
50. Krystal J.H., Webb E., Cooney N.L., Kranzler H.R., Southwick S.W., Heninger G.R., and Charney D.S. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Am. J. Psychiatry 153 (1996) 83-92
51. Kubzansky L.D., Koenen K.C., Spiro III A., Vokonas P.S., and Sparrow D. Prospective study of posttraumatic stress disorder symptoms and coronary heart disease in the normative aging study. Arch. Gen. Psychiatry 64 (2007) 109-116
52. Lee C.M., Javitch J.A., and Snyder S.H. Recognition sites for norepinephrine uptake: regulation by neurotransmitter. Science 220 (1983) 626-629
53. 1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. Biol. Psychiatry 36 (1994) 300-308
54. Li B.M., Mao Z.M., Wang M., and Mei Z.T. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 21 (1999) 601-610
55. Mao Z.M., Arnsten A.F., and Li B.M. Local infusion of an alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol. Psychiatry 46 (1999) 1259-1265
56. Mayorga A.J., Dalvi A., Page M.E., Zimov-Levinson S., Hen R., and Lucki I. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J. Pharmacol. Exp. Ther. 298 (2001) 1101-1107
57. Miner L.H., Jedema H.P., Moore F.W., Blakely R.D., Grace A.A., and Sesack S.R. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. J. Neurosci. 26 (2006) 1571-1578
58. Mitsushima D., Yamada K., Takase K., Funabashi T., and Kimura F. Sex differences in the basolateral amygdala: the extracellular levels of serotonin and dopamine, and their responses to restraint stress in rats. Eur. J. Neurosci. 24 (2006) 3245-3254
59. Morgan III C.A., Wang S., Southwick S.M., Rasmusson A., Hazlett G., Hauger R.L., and Charney D.S. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry 47 (2000) 902-909
60. Morgan III C.A., Rasmusson A.M., Wang S., Hoyt G., Hauger R.L., and Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol. Psychiatry 52 (2002) 136-142
61. 1B/1D receptor antagonist GR 127,935 on anxiolytic effect of citalopram in conditioned fear stress in the rat. Eur. J. Pharmacol. 586 (2008) 171-178
62. Neumaier J.F., Edwards E., and Plotsky P.M. 5-HT(1B) mRNA regulation in two animal models of altered stress reactivity. Biol. Psychiatry 51 (2002) 902-908
63. Neumeister A., Charney D.S., Belfer I., Geraci M., Holmes C., Sharabi Y., Alim T., Bonne O., Luckenbaugh D.A., Manji H., Goldman D., and Goldstein D.S. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet. Genomics 15 (2005) 143-149
64. Neylan T.C., Lenoci M., Samuelson K.W., Metzler T.J., Henn-Haase C., Hierholzer R.W., Lindley S.E., Otte C., Schoenfeld F.B., Yesavage J.A., and Marmar C.R. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am. J. Psychiatry 163 (2006) 2186-2188
65. Norris F.H. Epidemiology of trauma: frequency and impact of different potentially traumatic events on different demographic groups. J. Consult. Clin. Psychol. 60 (1992) 409-418
66. O'Donnell T., Hegadoren K.M., and Coupland N.C. Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder. Neuropsychobiology 50 (2004) 273-283
67. Pineyro G., and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51 (1999) 533-591
68. Price L.H., Malison R.T., McDougle C.J., McCance-Katz E.F., Owen K.R., and Heninger G.R. Neurobiology of tryptophan depletion in depression: effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology 17 (1997) 342-350
69. Rasmusson A.M., Hauger R.L., Morgan C.A., Bremner J.D., Charney D.S., and Southwick S.M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol. Psychiatry 47 (2000) 526-539
70. Rusnak M., Kvetnansky R., Jelokova J., and Palkovits M. Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats. Brain. Res. 899 (2001) 20-35
71. Rutter M. Resilience in the face of adversity. Protective factors and resistance to psychiatric disorder. Br. J. Psychiatry 147 (1985) 598-611
72. Sallinen J., Haapalinna A., MacDonald E., Viitamaa T., Lahdesmaki J., Rybnikova E., Pelto-Huikko M., Kobilka B.K., and Scheinin M. Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiatry 4 (1999) 443-452
73. Sari Y. Serotonin 1B receptors: from protein to physiological function and behavior. Neurosci. Biobehav. Rev. 28 (2004) 565-582
74. Schnurr P.P., Hayes A.F., Lunney C.A., McFall M., and Uddo M. Longitudinal analysis of the relationship between symptoms and quality of life in veterans treated for posttraumatic stress disorder. J. Consult. Clin. Psychol. 74 (2006) 707-713
75. Schramm N.L., McDonald M.P., and Limbird L.E. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21 (2001) 4875-4882
76. Shin L.M., Rauch S.L., and Pitman R.K. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann. N. Y. Acad. Sci. 1071 (2006) 67-79
77. Silva A.P., Xapelli S., Grouzmann E., and Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 331-347
78. Small K.M., Forbes S.L., Rahman F.F., Bridges K.M., and Liggett S.B. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275 (2000) 23059-23064
79. Smith D.G., Davis R.J., Gehlert D.R., and Nomikos G.G. Exposure to predator odor stress increases efflux of frontal cortex acetylcholine and monoamines in mice: comparisons with immobilization stress and reversal by chlordiazepoxide. Brain Res. 1114 (2006) 24-30
80. Southwick S.M., Krystal J.H., Morgan C.A., Johnson D., Nagy L.M., Nicolaou A., Heninger G.R., and Charney D.S. Abnormal noradrenergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 50 (1993) 266-274
81. Southwick S.M., Krystal J.H., Bremner J.D., Morgan III C.A., Nicolaou A.L., Nagy L.M., Johnson D.R., Heninger G.R., and Charney D.S. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 54 (1997) 749-758
82. Spurlock G., Buckland P., O'Donovan M., and McGuffin P. Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology 33 (1994) 433-440
83. Stahl S.M., Grady M.M., Moret C., and Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10 (2005) 732-747
84. 1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacology 32 (2007) 2163-2172
85. Stein D.J., Ipser J.C., and Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev. (2006) CD002795
86. Stein M.B., Walker J.R., Hazen A.L., and Forde D.R. Full and partial posttraumatic stress disorder: findings from a community survey. Am. J. Psychiatry 154 (1997) 1114-1119
87. Stein M.B., Walker J.R., and Forde D.R. Gender differences in susceptibility to posttraumatic stress disorder. Behav. Res. Ther. 38 (2000) 619-628
88. Stein M.B., Kennedy C.M., and Twamley E.W. Neuropsychological function in female victims of intimate partner violence with and without posttraumatic stress disorder. Biol. Psychiatry 52 (2002) 1079-1088
89. Stoltenberg S.F. Epistasis among presynaptic serotonergic system components. Behav. Genet. 35 (2005) 199-209
90. Swann A.C., Duman R., and Hewitt L. Desipramine binding: relationship to central and sympathetic noradrenergic activity. J. Neurochem. 44 (1985) 611-615
91. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178 (2001) 234-241
92. Thorsell A. Central neuropeptide Y in anxiety- and stress-related behavior and in ethanol intake. Ann. N. Y. Acad. Sci. 1148 (2008) 136-140
93. Tiet Q.Q., Bird H.R., Davies M., Hoven C., Cohen P., Jensen P.S., and Goodman S. Adverse life events and resilience. J. Am. Acad. Child Adolesc. Psychiatry 37 (1998) 1191-1200
94. Ursano R.J., Li H., Zhang L., Hough C.J., Fullerton C.S., Benedek D.M., Grieger T.A., and Holloway H.C. Models of PTSD and traumatic stress: the importance of research "from bedside to bench to bedside". Prog. Brain Res. 167 (2008) 203-215
95. Vasterling J.J., Duke L.M., Brailey K., Constans J.I., Allain Jr. A.N., and Sutker P.B. Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons. Neuropsychology 16 (2002) 5-14
96. Verge D., Daval G., Marcinkiewicz M., Patey A., el Mestikawy S., Gozlan H., and Hamon M. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci. 6 (1986) 3474-3482
97. Weinshenker D., White S.S., Javors M.A., Palmiter R.D., and Szot P. Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res. 946 (2002) 239-246
98. Welner S.A., De Montigny C., Desroches J., Desjardins P., and Suranyi-Cadotte B.E. Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment. Synapse. 4 (1989) 347-352
99. Whitaker-Azmitia P.M., and Azmitia E.C. Stimulation of astroglial serotonin receptors produces culture media which regulates growth of serotonergic neurons. Brain Res. 497 (1989) 80-85
100. 1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res. 528 (1990) 155-158
101. Yehuda R., Brand S., and Yang R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry 59 (2006) 660-663
102. Yehuda R., Flory J.D., Southwick S., and Charney D.S. Developing an agenda for translational studies of resilience and vulnerability following trauma exposure. Ann. N. Y. Acad. Sci. 1071 (2006) 379-396
103. Zatzick D.F., Marmar C.R., Weiss D.S., Browner W.S., Metzler T.J., Golding J.M., Stewart A., Schlenger W.E., and Wells K.B. Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am. J. Psychiatry. 154 (1997) 1690-1695
104. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., Manuck S.B., Brown S.M., Hauger R.L., Stohler C.S., Zubieta J.K., and Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 452 (2008) 997-1001
105. Zhu M.Y., Klimek V., Dilley G.E., Haycock J.W., Stockmeier C., Overholser J.C., Meltzer H.Y., and Ordway G.A. Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol. Psychiatry 46 (1999) 1275-1286